Suppr超能文献

2 型糖尿病的管理:不断演变的 2 型糖尿病患者治疗策略。

Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.

机构信息

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.

出版信息

Metabolism. 2011 Jan;60(1):1-23. doi: 10.1016/j.metabol.2010.09.010.

Abstract

The prevalence of type 2 diabetes continues to increase at an alarming rate around the world, with even more people being affected by prediabetes. Although the pathogenesis and long-term complications of type 2 diabetes are fairly well known, its treatment has remained challenging, with only half of the patients achieving the recommended hemoglobin A(1c) target. This narrative review explores the pathogenetic rationale for the treatment of type 2 diabetes, with the view of fostering better understanding of the evolving treatment modalities. The diagnostic criteria including the role of hemoglobin A(1c) in the diagnosis of diabetes are discussed. Due attention is given to the different therapeutic maneuvers and their utility in the management of the diabetic patient. The evidence supporting the role of exercise, medical nutrition therapy, glucose monitoring, and antiobesity measures including pharmacotherapy and bariatric surgery is discussed. The controversial subject of optimum glycemic control in hospitalized and ambulatory patients is discussed in detail. An update of the available pharmacologic options for the management of type 2 diabetes is provided with particular emphasis on newer and emerging modalities. Special attention has been given to the initiation of insulin therapy in patients with type 2 diabetes, with explanation of the pathophysiologic basis for insulin therapy in the ambulatory diabetic patient. A review of the evidence supporting the efficacy of the different preventive measures is also provided.

摘要

2 型糖尿病的患病率在全球范围内以惊人的速度持续上升,更多的人受到糖尿病前期的影响。尽管 2 型糖尿病的发病机制和长期并发症已经相当清楚,但治疗仍然具有挑战性,只有一半的患者达到了推荐的血红蛋白 A1c 目标。这篇叙述性评论探讨了 2 型糖尿病治疗的发病机制基础,以期更好地理解不断发展的治疗方式。讨论了包括血红蛋白 A1c 在糖尿病诊断中的作用在内的诊断标准。还特别关注了不同的治疗手段及其在糖尿病患者管理中的应用。讨论了支持运动、医学营养治疗、血糖监测以及包括药物治疗和减肥手术在内的抗肥胖措施作用的证据。详细讨论了住院和门诊患者最佳血糖控制的争议性问题。提供了管理 2 型糖尿病的现有药物选择的最新信息,特别强调了新出现的治疗方式。特别关注了在 2 型糖尿病患者中启动胰岛素治疗的问题,并解释了在门诊糖尿病患者中胰岛素治疗的病理生理基础。还提供了支持不同预防措施有效性的证据综述。

相似文献

1
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.
Metabolism. 2011 Jan;60(1):1-23. doi: 10.1016/j.metabol.2010.09.010.
2
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.

引用本文的文献

1
Antidiabetic potential of (Lour.) Merr.: a review of and studies.
Front Pharmacol. 2025 Aug 14;16:1646591. doi: 10.3389/fphar.2025.1646591. eCollection 2025.
3
Green Synthesis of Red Fluorescent Graphene Quantum Dots Using Leaves: Exploring Antidiabetic and Antioxidant Potential.
Int J Biomater. 2025 Feb 18;2025:5841012. doi: 10.1155/ijbm/5841012. eCollection 2025.
4
The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus.
Biomimetics (Basel). 2025 Jan 14;10(1):49. doi: 10.3390/biomimetics10010049.
6
New semisynthetic α-glucosidase inhibitor from a doubly-chemically engineered extract.
Nat Prod Bioprospect. 2025 Jan 5;15(1):4. doi: 10.1007/s13659-024-00488-2.
8
Biological Potential of Extracts: α-Glucosidase and Antibiofilm Activities In Vitro.
Molecules. 2024 Oct 26;29(21):5063. doi: 10.3390/molecules29215063.

本文引用的文献

1
Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.
Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):538-45. doi: 10.1161/CIRCOUTCOMES.109.911461. Epub 2010 Aug 24.
2
New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
Pharmacol Biochem Behav. 2010 Nov;97(1):63-83. doi: 10.1016/j.pbb.2010.07.020. Epub 2010 Aug 3.
3
Hypothalamic AMP-activated protein kinase regulates glucose production.
Diabetes. 2010 Oct;59(10):2435-43. doi: 10.2337/db10-0221. Epub 2010 Aug 3.
4
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207.
6
A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat.
Eur J Pharmacol. 2010 Aug 25;640(1-3):250-6. doi: 10.1016/j.ejphar.2010.04.054. Epub 2010 May 11.
8
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Vasc Health Risk Manag. 2010 Mar 24;6:145-55. doi: 10.2147/vhrm.s8216.
9
Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
Expert Opin Investig Drugs. 2010 Apr;19(4):489-512. doi: 10.1517/13543781003640169.
10
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验